Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
VSTM's Cash to Debt is ranked higher than
76% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. VSTM: No Debt )
Ranked among companies with meaningful Cash to Debt only.
VSTM' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6548
N/A
No Debt
Interest Coverage No Debt
VSTM's Interest Coverage is ranked higher than
53% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VSTM: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VSTM' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -0.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -54.80
VSTM's ROE (%) is ranked lower than
65% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. VSTM: -54.80 )
Ranked among companies with meaningful ROE (%) only.
VSTM' s ROE (%) Range Over the Past 10 Years
Min: -82.34  Med: -51.76 Max: -39.63
Current: -54.8
-82.34
-39.63
ROA (%) -50.13
VSTM's ROA (%) is ranked lower than
69% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. VSTM: -50.13 )
Ranked among companies with meaningful ROA (%) only.
VSTM' s ROA (%) Range Over the Past 10 Years
Min: -47.67  Med: -42.10 Max: -37.77
Current: -50.13
-47.67
-37.77
ROC (Joel Greenblatt) (%) -2300.31
VSTM's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. VSTM: -2300.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VSTM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7948.21  Med: -5742.30 Max: -3102.26
Current: -2300.31
-7948.21
-3102.26
» VSTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

VSTM Guru Trades in Q1 2015

Paul Tudor Jones 10,666 sh (New)
First Eagle Investment 427,622 sh (+41.31%)
Jim Simons 107,100 sh (-47.70%)
» More
Q2 2015

VSTM Guru Trades in Q2 2015

Jim Simons 148,444 sh (+38.60%)
First Eagle Investment 427,622 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q3 2015

VSTM Guru Trades in Q3 2015

Jim Simons Sold Out
First Eagle Investment 310,177 sh (-27.46%)
» More
Q4 2015

VSTM Guru Trades in Q4 2015

Jim Simons 84,945 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with VSTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.39
VSTM's P/B is ranked higher than
98% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. VSTM: 0.39 )
Ranked among companies with meaningful P/B only.
VSTM' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 4.9
Current: 0.39
0
4.9
EV-to-EBIT 1.36
VSTM's EV-to-EBIT is ranked higher than
86% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. VSTM: 1.36 )
Ranked among companies with meaningful EV-to-EBIT only.
VSTM' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 1.35
Current: 1.36
0
1.35
EV-to-EBITDA 1.37
VSTM's EV-to-EBITDA is ranked higher than
87% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 15.20 vs. VSTM: 1.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
VSTM' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 1.36
Current: 1.37
0
1.36
Current Ratio 11.15
VSTM's Current Ratio is ranked higher than
77% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. VSTM: 11.15 )
Ranked among companies with meaningful Current Ratio only.
VSTM' s Current Ratio Range Over the Past 10 Years
Min: 10.36  Med: 14.15 Max: 30.79
Current: 11.15
10.36
30.79
Quick Ratio 11.15
VSTM's Quick Ratio is ranked higher than
78% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. VSTM: 11.15 )
Ranked among companies with meaningful Quick Ratio only.
VSTM' s Quick Ratio Range Over the Past 10 Years
Min: 10.36  Med: 14.15 Max: 30.79
Current: 11.15
10.36
30.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.38
VSTM's Price/Net Cash is ranked higher than
99% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: 5.67 vs. VSTM: 0.38 )
Ranked among companies with meaningful Price/Net Cash only.
VSTM' s Price/Net Cash Range Over the Past 10 Years
Min: 0.61  Med: 3.09 Max: 5.77
Current: 0.38
0.61
5.77
Price/Net Current Asset Value 0.38
VSTM's Price/Net Current Asset Value is ranked higher than
99% of the 883 Companies
in the Global Biotechnology industry.

( Industry Median: 5.05 vs. VSTM: 0.38 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VSTM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.6  Med: 3.06 Max: 5.7
Current: 0.38
0.6
5.7
Price/Tangible Book 0.37
VSTM's Price/Tangible Book is ranked higher than
99% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. VSTM: 0.37 )
Ranked among companies with meaningful Price/Tangible Book only.
VSTM' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.59  Med: 2.40 Max: 3.87
Current: 0.37
0.59
3.87
Earnings Yield (Greenblatt) (%) 75.17
VSTM's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. VSTM: 75.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VSTM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -118.53  Med: 0.00 Max: 169.33
Current: 75.17
-118.53
169.33

More Statistics

EPS $ -1.83
Beta1.91
Short Percentage of Float6.01%
52-Week Range $1.07 - 12.35
Shares Outstanding(Mil)36.93

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil)
EPS($) -1.67 -1.49 -1.33 -0.80
EPS without NRI($) -1.67 -1.49 -1.33 -0.80

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2VS.Germany,
Verastem Inc was incorporated under the laws of the State of Delaware in August 2010. The Company is a biopharmaceutical company engaged in discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. A cancer stem cell is a particularly aggressive type of tumor cell, resistant to conventional cancer therapy, that it believes is an underlying cause of tumors, their recurrence and metastasis. It licenses its EMT technology from the Whitehead Institute for Biomedical Research, an affiliate of the Massachusetts Institute of Technology, or MIT, and the President and Fellows of Harvard College, or Harvard. Its advanced product candidates are VS-6063, VS-4718 and VS-5584. It is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including mesothelioma, ovarian and lung. The Company's solution is to discover and develop a next generation of oncology therapeutics targeting CSCs along with companion diagnostics. It believes that by developing therapeutics that target CSCs it can address the problem of cancer recurrence and metastasis. The Company has three product candidates currently in clinical trials including the focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718, and the dual mTORC1/2 and PI3K inhibitor VS-5584. The Company's competitors include Astellas Pharma Inc., Celgene, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc. and others. There are also biotechnology companies of various sizes that are developing therapies against CSCs, including OncoMed Pharmaceuticals, Inc., Boston Biomedical Inc. (a division of Dainippon Sumitomo Corp) and Stemline Therapeutics, Inc. and others. The Company is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes.
» More Articles for VSTM

Headlines

Articles On GuruFocus.com
5 Deep Value or Net-Net Investment Ideas Feb 09 2016 

More From Other Websites
Verastem to Present at Upcoming Investor Conferences Jan 27 2016
Verastem to Present at Upcoming Investor Conferences Jan 27 2016
Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint... Jan 21 2016
Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint... Jan 21 2016
Former US president Jimmy Carter Says His Brain Cancer Has Disappeared Jan 20 2016
VERASTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 08 2016
Washington University in St. Louis Initiates Clinical Study of Verastem’s VS-6063 in Combination... Jan 06 2016
Washington University in St. Louis Initiates Clinical Study of Verastem’s VS-6063 in Combination... Jan 06 2016
Is OncoGenex Pharmaceuticals Inc (OGXI) A Good Stock To Buy? Dec 09 2015
VERASTEM, INC. Financials Dec 08 2015
Applying Lessons from KBIO Dec 08 2015
Hedge Funds Are Selling Verastem Inc (VSTM) Nov 24 2015
Biotechs Under 20 Dollars Poised to Breakout Nov 23 2015
VERASTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 09 2015
Verastem Reports Third Quarter 2015 Financial and Corporate Results Nov 09 2015
Verastem reports 3Q loss Nov 09 2015
Verastem reports 3Q loss Nov 09 2015
VERASTEM, INC. Files SEC form 10-Q, Quarterly Report Nov 09 2015
Verastem Reports Third Quarter 2015 Financial and Corporate Results Nov 09 2015
4 Stocks Under $10 Making Big Up Moves on Big Volume Nov 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK